BFS
RGC icon

Bare Financial Services’s Regencell Bioscience RGC Stock Holding History

Bare Financial Services’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$183 Buy
30
+16
+114% +$384 ﹤0.01% 1773
2026
Q1 		$356 Buy
+14
New +$396 ﹤0.01% 1692

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Amundi
Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Bare Financial Services's RGC Position: Q2 2026 in Review

Bare Financial Services increased its Regencell Bioscience (RGC) stake by 114% in Q2 2026, buying an estimated $384 and bringing the position to 30 shares worth $183. The position accounts for ﹤0.01% of the portfolio, ranked #1773.

Bare Financial Services first reported a position in RGC in Q1 2026 and has held it in 2 quarters since. The position peaked at $356 in Q1 2026. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

  • Bare Financial Services held 30 shares of Regencell Bioscience worth $183 as of Q2 2026.
  • Bare Financial Services bought 16 Regencell Bioscience shares in Q2 2026, an estimated $384.
  • Regencell Bioscience made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1773 holding.
  • Bare Financial Services first reported a position in Regencell Bioscience in Q1 2026 and has held it in 2 quarters since.
  • Bare Financial Services's Regencell Bioscience position peaked at $356 in Q1 2026.
  • 35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.